• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Sanofi

    5/28/26 6:06:37 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNY alert in real time by email
    SD 1 d271722dsd.htm SD SD

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM SD

    Specialized Disclosure Report

    SANOFI

    (Exact name of registrant as specified in its charter)

     

    Republic of France   001-31368   98-0346613
    (State or other jurisdiction   (Commission   (IRS Employer
    of incorporation or organization)   File Number)   Identification No.)
    46 avenue de la Grande Armée Paris, France   75017
    (Address of principal executive offices)   (Zip Code)

    Alexandra Roger

    (+33) 1 53 77 48 98

    (Name and telephone number, including area code, of the person to contact in connection with this report.)

    Check the appropriate box to indicate the rule pursuant to which this Form is being submitted, and provide the period to which the information in this Form applies:

     

    x   

    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2025.

      
        

    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended      .


    Section 1 – Conflict Minerals Disclosure

    Item 1.01 Conflict Minerals Disclosure and Report

    Conflict Minerals Disclosure

    Sanofi (including its consolidated subsidiaries, the “Company”) is filing this Form SD pursuant to Rule 13p-1 under the Securities Exchange Act of 1934 (“Rule 13p-1”) for the reporting period from January 1, 2025, to December 31, 2025 (the “Reporting Period”).

    Rule 13p-1, through Form SD, requires disclosure of certain information if a company manufactures or contracts to manufacture products for which certain “conflict minerals” (as defined below) are necessary to the functionality or production of such products. Form SD defines “conflict minerals” as: (i) (a) columbite-tantalite, (b) cassiterite, (c) gold and (d) wolframite, or their derivatives, which are currently limited to tantalum, tin and tungsten; or (ii) any other mineral or its derivatives determined by the U.S. Secretary of State to be financing conflict in the Democratic Republic of the Congo or an “adjoining country,” as such term is defined in Form SD (collectively, the “Covered Countries”).

    The Company’s operations may at times manufacture, or contract to manufacture, products for which conflict minerals are necessary to the functionality or production of those products (collectively, the “products”).

    Reasonable Country of Origin Inquiry

    As required by Form SD, the Company has conducted a good faith reasonable country of origin inquiry (“RCOI”) regarding the conflict minerals that are necessary to the functionality or production of its products during the Reporting Period, which the Company refers to as the “Subject Minerals,” to determine whether any such Subject Minerals originated in the Covered Countries and/or whether any of the Subject Minerals were from recycled or scrap sources, in accordance with Form SD and related guidance provided by the Securities and Exchange Commission (“SEC”). In accordance with SEC Staff Guidance with respect to Rule 13p-1, the Company excluded packaging materials from this review.

    The Company’s global supply chain is complex. In the course of its business operations, the Company may purchase materials and components containing Subject Minerals. These materials and components may, in turn, be included in the Company’s products. Because the Company does not purchase conflict minerals directly from mines, smelters or refiners, there are many third parties in the supply chain between the Company and the original sources of conflict minerals. The Company’s immediate suppliers, in turn, typically are also downstream in the minerals supply chain and have similar challenges in achieving supply chain transparency. As a result, the Company relies on its direct suppliers of materials, with which the Company has business relationships, to provide information regarding the origin of any conflict minerals that are included in their products.

    The Company’s RCOI process and results regarding the Subject Minerals include as described below.

     

      •  

    The Company’s procurement and manufacturing and supply departments worked together to search the Company’s database to identify where Subject Minerals were used in its products. As a result of this process, the Company identified certain of its immediate, potentially in-scope suppliers of materials that provided materials or components that may contain Subject Minerals (collectively, the “Covered Suppliers”).

     

      •  

    The Company put in place a consultation of the Covered Suppliers, with the assistance of a third-party service vendor (the “Vendor”) with expertise in supply chain due diligence, to assist in data collection and identifying risks of the presence of Subject Minerals originating from Covered Countries in the Company’s products, using the Conflict Minerals Reporting Template (“CMRT”) published by the Responsible Materials Initiative. The Company, with the assistance of the Vendor, inventoried the responses received from the Covered Suppliers.


      •  

    An escalation process was conducted with Covered Suppliers who continued to be non-responsive, despite reminder e-mails after the above contacts were made, or whose initial (or subsequent) response was not complete or otherwise warranted clarification or confirmation. Using a risk-based approach, the Company, with the assistance of the Vendor, evaluated responses from the Covered Suppliers. The Company, with the assistance of the Vendor, engaged certain Covered Suppliers, holding discussions to ensure that the Company’s inquiries regarding conflict minerals were understood and complied with.

    On the basis of the RCOI process described above, the Company has no reason to believe that the Subject Minerals contained in its products during the Reporting Period originated in the Covered Countries and not from recycled or scrap sources.

    As required by Form SD, the disclosure contained in this Form SD regarding the Company’s RCOI is available on the Company’s website located at http://www.sanofi.com. The content on, or accessible through, any web site referred to in this Form SD is not incorporated by reference into this Form SD unless expressly noted.

     

    Item 1.02.

     Exhibit.

    Not applicable.

    Section 2 – Resource Extraction Issuer Disclosure

    Not applicable.

    Section 3 – Exhibits

    Item 3.01    Exhibits

    Not applicable.

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

    SANOFI

     

     By:  /s/ Jean-Yves Rotté-Geoffroy

       Date: 26 May, 2026

     Name: Jean-Yves Rotté-Geoffroy

      

     Title:  Chief Procurement Officer

      
    Get the next $SNY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNY

    DatePrice TargetRatingAnalyst
    5/1/2026Overweight → Equal-Weight
    Morgan Stanley
    4/20/2026$50.00Outperform → Neutral
    BNP Paribas Exane
    2/12/2026Buy → Neutral
    BofA Securities
    1/27/2026Neutral
    Citigroup
    1/16/2026Buy → Neutral
    UBS
    1/6/2026Overweight → Equal Weight
    Barclays
    12/9/2025Buy → Neutral
    Guggenheim
    12/8/2025Overweight → Neutral
    Analyst
    More analyst ratings

    $SNY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sanofi invests $294M to expand AI Center of Excellence in Toronto and accelerate innovation for patients

    Expansion to create 50 new high-skilled jobs in AI and reinforce Sanofi's long-term commitment to OntarioInvest Ontario Fund to contribute a conditional grant of up to $5 millionPartnership with the Province of Ontario and Toronto's strong AI talent pool key drivers in site selectionTORONTO, May 4, 2026 /CNW/ - Sanofi, an R&D-driven, AI-powered biopharma company and Canada's largest biopharma manufacturer, is expanding its global Artificial Intelligence (AI) Centre of Excellence in Toronto, deepening its investment in Ontario and growing AI talent to develop and manufacture life-changing medicines and vaccines faster than ever before.

    5/4/26 1:00:00 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi becomes market authorization holder for Nuvaxovid® in Canada, expanding COVID-19 vaccine choices for Canadians

    Nuvaxovid, a non-mRNA COVID-19 vaccine, will be made available in Canada by Sanofi for the fall 2026-2027 seasonProvincial and territorial availability will be confirmed pending ongoing discussions and provincial assessmentsTransfer of market authorization from Novavax follows the strategic agreement signed between the two companies in May 2024This underscores Sanofi's commitment to public health and vaccine innovation in CanadaTORONTO, April 9, 2026 /CNW/ - Sanofi today announces it has become the market authorization holder in Canada for Nuvaxovid, a non-mRNA protein-based COVID-19 vaccine. Nuvaxovid represents another step in Sanofi's commitment to building a diverse portfolio of best-in-

    4/9/26 10:00:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi announces leadership evolution in Specialty Care Business Unit

    CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026. Manuela will succeed Brian Foard, who has decided to leave the company as of February 28, 2026, having accepted an external leadership opportunity. Brian joined Sanofi in 2017 and has held several senior leadership roles, most recently leading the Specialty Care Global Business Unit and serving as a member of the Executive Committee. During his tenure, Sanofi's Specialty Care strengthened its global position, driven by the launches of key medicines such as Dupixent across multiple indications and geographies. Manuela will lead Sanofi's Spe

    2/17/26 8:30:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XYZAL ALLERGY 24HR issued to CHATTEM SANOFI

    Submission status for CHATTEM SANOFI's drug XYZAL ALLERGY 24HR (SUPPL-10) with active ingredient LEVOCETIRIZINE DIHYDROCHLORIDE has changed to 'Approval' on 05/20/2026. Application Category: NDA, Application Number: 209089, Application Classification: Labeling

    5/21/26 4:47:30 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    March 28, 2025 - FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors

    For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi

    3/28/25 10:17:55 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    February 14, 2025 - FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

    For Immediate Release: February 14, 2025 Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Meri

    2/14/25 3:00:13 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    SEC Filings

    View All

    SEC Form SD filed by Sanofi

    SD - Sanofi (0001121404) (Filer)

    5/28/26 6:06:37 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Sanofi

    6-K - Sanofi (0001121404) (Filer)

    5/27/26 10:31:45 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 13F-HR filed by Sanofi

    13F-HR - Sanofi (0001121404) (Filer)

    5/7/26 8:47:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sanofi downgraded by Morgan Stanley

    Morgan Stanley downgraded Sanofi from Overweight to Equal-Weight

    5/1/26 3:53:16 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi downgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane downgraded Sanofi from Outperform to Neutral and set a new price target of $50.00

    4/20/26 8:24:56 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi downgraded by BofA Securities

    BofA Securities downgraded Sanofi from Buy to Neutral

    2/12/26 7:23:56 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Sanofi converted options into 3,088,502 units of Common Stock and bought $1,000,005 worth of Common Stock (66,667 units at $15.00)

    4 - Sanofi (0001121404) (Reporting)

    8/2/21 8:34:24 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Sanofi

    3 - Sanofi (0001121404) (Reporting)

    7/28/21 8:32:04 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    Leadership Updates

    Live Leadership Updates

    View All

    Sanofi invests $294M to expand AI Center of Excellence in Toronto and accelerate innovation for patients

    Expansion to create 50 new high-skilled jobs in AI and reinforce Sanofi's long-term commitment to OntarioInvest Ontario Fund to contribute a conditional grant of up to $5 millionPartnership with the Province of Ontario and Toronto's strong AI talent pool key drivers in site selectionTORONTO, May 4, 2026 /CNW/ - Sanofi, an R&D-driven, AI-powered biopharma company and Canada's largest biopharma manufacturer, is expanding its global Artificial Intelligence (AI) Centre of Excellence in Toronto, deepening its investment in Ontario and growing AI talent to develop and manufacture life-changing medicines and vaccines faster than ever before.

    5/4/26 1:00:00 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi announces leadership evolution in Specialty Care Business Unit

    CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- Sanofi today announced the appointment of Manuela Buxo as Head of Specialty Care, effective March 1, 2026. Manuela will succeed Brian Foard, who has decided to leave the company as of February 28, 2026, having accepted an external leadership opportunity. Brian joined Sanofi in 2017 and has held several senior leadership roles, most recently leading the Specialty Care Global Business Unit and serving as a member of the Executive Committee. During his tenure, Sanofi's Specialty Care strengthened its global position, driven by the launches of key medicines such as Dupixent across multiple indications and geographies. Manuela will lead Sanofi's Spe

    2/17/26 8:30:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ITM Appoints Annette Breunig as Chief People Officer

    Global HR leader to drive ITM's long-term human resources strategy, support organizational development and corporate growth Garching / Munich, Germany, October 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Annette Breunig as Chief People Officer (CPO). Ms. Breunig brings over 25 years of HR leadership experience at international pharmaceutical, manufacturing and technology companies, including at Siemens AG (FRA: SIE) and Sanofi (NASDAQ:SNY). At ITM, Ms. Breunig will lead the HR team in shaping strategies that unify the organization to achieve both team and business growth objectives while empowering em

    10/13/25 5:00:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    Financials

    Live finance-specific insights

    View All

    Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

    Initiative spans an IVD assay and a new Revvity Omics lab-developed test to expand clinical testing for early-stage disease screening Revvity, Inc. (NYSE:RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Sanofi (NASDAQ:SNY). Revvity will develop a T1D 4-plex in vitro diagnostic (IVD) assay based on its existing research-use (RUO) 3-plex assay. T1D is a lifelong, progressive autoimmune condition that occurs when the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. Early detection of T1D enables options for patients and caregivers to improve outcome

    10/2/25 8:00:00 AM ET
    $RVTY
    $SNY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

    Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolioPARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, have entered into an agreement under which Sanofi will acquire Blueprint. The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU

    6/2/25 1:25:00 AM ET
    $BPMC
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

    - Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer's disease – - Companies expect transaction to close in third quarter of 2025 - WATERTOWN, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for

    5/21/25 7:30:46 PM ET
    $SNY
    $VIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $SNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sanofi

    SC 13G/A - Sanofi (0001121404) (Subject)

    11/7/24 2:49:36 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Sanofi

    SC 13G - Sanofi (0001121404) (Filed by)

    5/31/24 4:30:55 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Sanofi (Amendment)

    SC 13G/A - Sanofi (0001121404) (Subject)

    2/14/24 3:57:49 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care